This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RPTP (RPTP) (RPTP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About (RPTP) Stock (NASDAQ:RPTP) 30 days 90 days 365 days Advanced Chart Get (RPTP) alerts:Sign Up Key Stats Today's Range$9.00▼$9.0050-Day Range N/A52-Week Range$2.94▼$9.05VolumeN/AAverage Volume1.42 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate), is indicated as an orphan medicinal product for the management of nephropathic cystinosis. Its QUINSAIR is a formulation of the antibiotic drug levofloxacin, suitable for inhalation via a nebulizer. It is engaged in developing MP-376 for non-CF bronchiectasis (BE) and nontuberculous mycobacteria (NTM) lung infections. It is also engaged in developing RP105 and RP106 for various diseases. Read More Receive RPTP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (RPTP) and its competitors with MarketBeat's FREE daily newsletter. Email Address RPTP Stock News HeadlinesNew weather alert radios available for the deaf and hard of hearing in KentuckySeptember 29, 2024 | msn.comNew study reveals major link between sugar and Alzheimer's diseaseSeptember 28, 2024 | msn.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.July 27 at 2:00 AM | Porter & Company (Ad)National Bank of Canada Pref Share NA.PR.CMay 18, 2024 | morningstar.comMKey Insights into LAR-RPTP's Synaptic Regulation via Microexon Molecular CodesMarch 30, 2024 | msn.comResearch suggests fine-tuning of specific excitatory synapse traits could lead to new brain disease treatmentsMarch 29, 2024 | msn.comAuckland Council bids to untangle transport from governmentAugust 17, 2023 | msn.comAmigo scrambles for survival as £45m emergency cash talks failMarch 10, 2023 | msn.comSee More Headlines RPTP Stock Analysis - Frequently Asked Questions What other stocks do shareholders of (RPTP) own? Based on aggregate information from My MarketBeat watchlists, some other companies that (RPTP) investors own include Bristol Myers Squibb (BMY), BioCryst Pharmaceuticals (BCRX), OPKO Health (OPK), Cheniere Energy (LNG), Novavax (NVAX), CTI BioPharma (CTIC) and Freeport-McMoRan (FCX). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:RPTP CIK1070698 Webwww.horizonpharma.com Phone+1-415-4086200FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:RPTP) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredThe big winner of Crypto week?It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bit...Weiss Ratings | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (RPTP) Please log in to your account or sign up in order to add this asset to your watchlist. Share (RPTP) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.